Neural Therapeutics (FRA:M6B) Buyback Yield %: 0.00 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Buyback Yield %?

Neural Therapeutics FRA:M6B Buyback Yield % is 0.00 as of Jul. 26, 2026. The stock has 1 warning sign investors should review. Among 738 Biotechnology companies, Neural Therapeutics ranks worse than 135501.22% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Neural Therapeutics's current buyback yield was 0.00%.

Neural Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Buyback Yield % Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Buyback Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -18.75

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.55 -20.97 0.00 0.00

FRA:M6B vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Neural Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neural Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neural Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Neural Therapeutics's Buyback Yield % falls into.


Neural Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Neural Therapeutics's Buyback Yield for the fiscal year that ended in Jul. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.291) / 1.5522675
=-18.75%

Neural Therapeutics's annualized Buyback Yield for the quarter that ended in Jan. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 1.4339585
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Neural Therapeutics (FRA:M6B) has a Buyback Yield % of 0.00 as of Jul. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neural Therapeutics and its competitors. According to the industry distribution chart, Neural Therapeutics ranks #999999 out of 738 companies in the Biotechnology industry.
Is Neural Therapeutics' Buyback Yield % too high?
Neural Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Neural Therapeutics ranks #999999 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neural Therapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neural Therapeutics ranks #999999 out of 738 companies for Buyback Yield %. This places Neural Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (FRA:M6B) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Neural Therapeutics (FRA:M6B), the current Buyback Yield % is 0.00 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges NURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.